Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Language
Document Type
Year range
1.
Immuno-Oncology and Technology ; Conference: ESMO Immuno-Oncology Congress 2022. Geneva Switzerland. 16(Supplement 1) (no pagination), 2022.
Article in English | EMBASE | ID: covidwho-2210537

ABSTRACT

Background: Despite advances in the treatment of mCRC combining chemotherapy regimens with biologics, most patients (pts) still progress within 11 months of receiving 1L chemotherapy. Addition of novel therapies to the standard of care (SoC) to improve antitumor activity is urgently needed. The randomized part 2 of COLUMBIA-1 (NCT04068610) evaluated the safety and efficacy of combining SoC (bevacizumab [BEV] + FOLFOX) with the PD-L1 inhibitor durvalumab (D) and the anti-CD73 monoclonal antibody oleclumab (O). Method(s): Pts with previously untreated, MSS-mCRC and ECOG PS <=1 received either SoC alone or SoC + D (1500 mg, Q4W) + O (3000 mg Q2W x4 then Q4W) in the experimental arm (EXP). The primary endpoint was objective response rate (ORR) per investigator assessed RECIST v1.1. Result(s): As of 10 Dec 2021, 52 pts were enrolled, of whom 51 were response evaluable. The confirmed ORR with SoC was 44.0% (95% confidence interval [CI], 24.4-65.1%) compared to 61.5% (95% CI, 40.6-79.8%) in the EXP arm. Median OS was not reached (SoC) vs 19.1 mos (EXP);median PFS was 11.1 mos (SoC) vs 10.9 mos (EXP;Table). Grade >=3 treatment emergent adverse events (TEAEs) occurred in 76.9% of pts in SoC and 65.4% EXP. Fatal TEAEs (all unrelated) were observed in 3 pts in the EXP arm: 1 with sepsis and 2 with intestinal perforation. One pt with intestinal perforation deemed related to BEV experienced fatal peritonitis. In the SoC arm, there was a single fatal COVID-19 TEAE. The most frequent treatment-related AEs in the EXP arm were diarrhea (38.5%), peripheral sensory neuropathy (38.5%) and fatigue (26.9%). There was no identified association between CD73 expression and clinical benefit. Conclusion(s): Addition of D + O to FOLFOX + BEV SoC showed a moderate response increase without PFS benefit vs SoC alone. Safety was consistent with known safety profiles. [Formula presented] Clinical trial identification: NCT04068610. Editorial acknowledgement: Editing support for this , under the direction of the authors, was provided by Catherine Crookes of Ashfield MedComms (Macclesfield, UK), an Inizio company, and was funded by AstraZeneca. Legal entity responsible for the study: AstraZeneca. Funding(s): AstraZeneca. Disclosure: N.H. Segal: Financial Interests, Personal, Advisory Board: Immunocore, PsiOxus, Roche/Genentech, BI, Revitope, ABL Bio, Novartis, GSK, AstraZeneca, Numab;Financial Interests, Personal, Research Grant: Regeneron, Immunocore, PureTech, AstraZeneca, BMS, Merck, Pfizer, Roche/Genentech. J. Tie: Financial Interests, Personal, Invited Speaker, Honorarium: Novartis, Amgen, Merck Serono, Merck Sharp and Dohme, Pierre Fabre;Financial Interests, Personal, Advisory Board: Haystack Oncology, Amgen, Novartis, AstraZeneca, Merck Serono, Merck Sharp and Dohme, Pierre Fabre, BMS;Non-Financial Interests, Personal, Principal Investigator: AstraZeneca, Pfizer, Daiichi Sankyo, Novartis. S. Kopetz: Financial Interests, Personal, Ownership Interest: MolecularMatch, Lutris, Iylon;Financial Interests, Personal, Research Grant: Sanofi, Biocartis, Guardant Health, Array BioPharma, Genentech/Roche, EMD Serono, AstraZeneca, Novartis, Amgen, Lilly, Daiichi Sankyo;Financial Interests, Personal, Other: Genetech, EMD Serono, Merck, Holy Stone, Novartis, Lilly, BI, Boston Biomedical, AstraZeneca, Bayer Health, Pierre Fabre, Redx Pharma, Ipsen, Daiichi Sankyo, Natera, HalioDx, Lutris, Jacobio, Pfizer, Repare Therapeutics, Inivata, GSK, Jazz Pharmaceuticals, Iylon, Xilis, AbbVie, Amal Therapeutics, Gilead, Mirati, Flame Biosciences, Servier, Carina Biotechnology, Bicara Therapeutics, Endeavor BioMedicines, Numab Pharma, Johnson and Johnson/Janssen. M.P. Ducreux: Financial Interests, Personal, Invited Speaker: Roche, Beigene, MSD, Servier, Pierre Fabre, Amgen;Financial Interests, Personal, Advisory Board: Terumo, Roche, Merck Serono, Bayer, Daiichi Sankyo, Sotio;Financial Interests, Institutional, Research Grant: Keocyt, Roche, Bayer. E. Chen: Financial Interests, Personal, Advisory Board: AstraZeneca;Financial Interests, Personal, Princip l Investigator: AstraZeneca. R. Dienstmann: Financial Interests, Personal, Speaker's Bureau: Roche, BI, Ipsen, Amgen, Servier, Sanofi, Libbs, Merck Sharp and Dohme, Lilly, AstraZeneca;Financial Interests, Personal, Advisory Board: Roche, BI;Financial Interests, Personal, Research Grant: Merck, Pierre Fabre. A. Hollebecque: Financial Interests, Personal, Invited Speaker: Servier, Incyte, EISAI;Financial Interests, Personal, Advisory Board: Basilea, Tahio, Relay Theraeutics, QED Therapeutics, Debiopharm;Financial Interests, Institutional, Funding: Incyte;Financial Interests, Institutional, Research Grant: AstraZeneca;Non-Financial Interests, Personal, Principal Investigator, M19-345: AbbVie;Non-Financial Interests, Personal, Principal Investigator, CO42216: Roche;Non-Financial Interests, Personal, Principal Investigator, MCLA-158: Merus;Non-Financial Interests, Personal, Principal Investigator, SGNB6A: Seattle Genetics;Non-Financial Interests, Personal, Principal Investigator, TAS-120-202: Tahio;Non-Financial Interests, Personal, Principal Investigator, Krystal-10: Mirati;Non-Financial Interests, Personal, Principal Investigator, ADP-0033: Adaptimmune;Non-Financial Interests, Personal, Principal Investigator, ACT16902: Sanofi;Non-Financial Interests, Personal, Principal Investigator, C4201002: Pfizer;Non-Financial Interests, Personal, Principal Investigator, RLY-4008: Relay Therapeutics;Non-Financial Interests, Personal, Principal Investigator, CC-90011: Celgene/BMS;Non-Financial Interests, Personal, Principal Investigator, Loxo-IDH: Loxo/Lilly;Non-Financial Interests, Personal, Principal Investigator: AstraZeneca. M. Reilley: Financial Interests, Personal, Advisory Board: BMS, Helsinn, ZielBio. M.E. Elez Fernandez: Financial Interests, Personal, Invited Speaker: Novartis, Organon;Financial Interests, Personal, Advisory Board: Amgen, Bayer, F. Hoffman La Roche, Merck Serono, MSD, Pierre Fabre, Sanofi, Servier;Financial Interests, Institutional, Funding: Amgen, Array Biopharma, AstraZeneca, BeiGene, BI, BMS, Celgene, Debiopharm International SA, F. Hoffman La Roche, Genentech, HalioDX SAS, Hutchinson MediPharma International, Janssen-Cilag SA, Menarini, Merck ealth KgaA, MSD, Merus NV, Mirati, Novartis Farmaceutica SA, Pfizer, PharmaMar, Sanofi Aventis Recherche & Developpement, Servier, Taiho Pharma;Financial Interests, Personal, Other, ASCO Scientific Program Committee: Developmental Therapeutics - Immunotherapy: ASCO;Financial Interests, Personal, Other, Speaker of the ESMO Academy: ESMO;Financial Interests, Personal, Other, Coordinator of the SEOM +MIR Section of Residents and Young Assistants: SEOM;Financial Interests, Personal, Other, Travel, accommodations, expenses: Amgen, Array BioPharma, BMS, Merck Serono, Roche, Sanofi, Servier. J. Cosaert: Financial Interests, Personal, Full or part-time Employment: AstraZeneca;Financial Interests, Personal, Stocks/Shares: AstraZeneca;Financial Interests, Personal, Member: AstraZeneca. J. Cain: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. M. Hernandez: Financial Interests, Personal, Full or part-time Employment: AstraZeneca;Financial Interests, Personal, Stocks/Shares: AstraZeneca. N. Hewson: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. Z.A. Cooper: Financial Interests, Personal, Full or part-time Employment: AstraZeneca;Financial Interests, Personal, Stocks/Shares: AstraZeneca. M. Dressman: Financial Interests, Personal, Full or part-time Employment: AstraZeneca;Financial Interests, Personal, Stocks/Shares: AstraZeneca. J. Tabernero: Financial Interests, Personal, Advisory Role: Array BioPharma, AstraZeneca, Bayer, BI, Chugai, Daiichi Sankyo, F. Hoffman-La Roche Ltd, Genentech, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, Inspirna Inc, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandio Oncology, Scorpion Therapeutics, Seattle Genetics, Servier, Sotio Biotech, Taiho, Tessa Therapeutics, TheraMyc;Financial Interests, Personal, Stocks/Shares: Oniria Therapeutics;Financial Interests, Personal, Other, educational collaboration: Imedex/HMP, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education, Physicians Education Resource (PER). Copyright © 2022 European Society for Medical Oncology

3.
Annals of Oncology ; 32:S1245-S1246, 2021.
Article in English | EMBASE | ID: covidwho-1432833

ABSTRACT

Background: Knowledge of the career paths and employment situation of young medical oncologists is lacking. The aim of our study was to evaluate the current professional standing of young medical oncologists during COVID-19 pandemic in Spain. Methods: The SEOM +MIR section conducted a national online survey in May 2021 of young medical oncology consultants (<6 years of expertise) and last year medical oncology residents. Using the electronic mailing available in the SEOM database, professionals from Spain were invited. Results: A total of 136 responses were eligible in the preliminary analysis. 86 (63%) were women. 106 (78%) were consultants and 30 (22%) were residents. 92 (68%) performed standard clinical care and 10 (7%) research activity. 97 (71%) were subspecialized in a main area of interest and almost half of them, 60 (48%), chose it because it was the only option available after residency. 75 (55%) had considered different employment opportunities other than standard clinical care and 33 (25%) showed an interest in increasing their research activity. 68 (50%) had considered working in foreign countries: 40 (29%) in the European Union. The main reasons were: 35 (26%) thought it might increase their professional development and 29 (22%) argued for better salary conditions abroad. Furthermore, 109 (80%) believed the professional standing in Spain was worse than other countries. After finishing their residency, only 20 (14%) were offered a job at their training hospital. Solely, 17 (12%) participants had an indefinite employment contract. 25 (18%) had previously signed a COVID-19 temporary contract. 55 (40%) were worried about their employment stability. Conclusions: The availability of subspecializing in medical oncology may depend on the job opportunity after residency rather than personal interest. The abundance of temporary contracts could have influenced the employment stability concerns observed. Our work contributes and is consistent with the ESMO values focused on the wellbeing of medical oncology professionals. Future mentoring strategies should engage in building a long-term career path for young medical oncologists. Legal entity responsible for the study: SEOM +MIR Section. Funding: Has not received any funding. Disclosure: V. Pacheco-Barcia: Financial Interests, Personal, Invited Speaker, Speaker Fee: Eisai;Financial Interests, Personal, Invited Speaker, Speaker Fee: Merck;Financial Interests, Personal, Invited Speaker, Speaker Fee: Bristol Myers Squibb;Financial Interests, Personal, Invited Speaker, Speaker Fee: LEO Pharma;Financial Interests, Personal, Invited Speaker, Speaker Fee: Kyowa Kirin;Financial Interests, Personal, Invited Speaker, Speaker Fee: Grunenthal;Financial Interests, Personal, Invited Speaker, Speaker FEE: Prostakan;Financial Interests, Personal, Invited Speaker, Speaker Fee: Lilly;Other, Other: Merck. D.A. Sanchez: Financial Interests, Personal, Invited Speaker: Janssen;Non-Financial Interests, Personal and Institutional, Leadership Role, National Representative of Young Doctors of Promotion of Employment in Organización Médica Colegial: Spanish Medical Association;Non-Financial Interests, Personal and Institutional, Leadership Role: President of the Murcian Health Service Company Committee;Non-Financial Interests, Personal and Institutional, Leadership Role: Vice-representative from the European Junior Doctors (EJD) in Oncology Section in UEMS (Uropean Union of Medical Specialties);Non-Financial Interests, Personal, Other: Member of +MIR Section of the Spanish Society of Medical Oncology;Non-Financial Interests, Personal, Other: ESMO member;Non-Financial Interests, Personal, Other: SEOM member. B. Obispo: Financial Interests, Personal, Invited Speaker: Lilly;Financial Interests, Personal, Invited Speaker: Novartis;Financial Interests, Personal, Invited Speaker: Sanofi;Financial Interests, Personal, Invited Speaker: Fresenius;Financial Interests, Personal, Invited Speaker: Angelini Pharma;Financial Interests, Personal, Invited Speaker: Rovi;Financial Interes s, Personal, Invited Speaker: Leo Pharma. A. Quilez: Financial Interests, Personal, Invited Speaker: Roche;Financial Interests, Personal, Advisory Role: Clovis;Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb;Financial Interests, Personal, Speaker’s Bureau: GSK;Financial Interests, Personal, Advisory Role: GSK. A. Sesma: Financial Interests, Personal, Invited Speaker: MSD. D. Paez: Financial Interests, Personal, Advisory Role: Amgen;Financial Interests, Personal, Speaker’s Bureau: Amgen;Financial Interests, Personal, Speaker’s Bureau: F. Hoffman-La Roche Ltd;Financial Interests, Personal, Advisory Role: Sanofi;Financial Interests, Personal, Advisory Role: Ipsen;Financial Interests, Personal, Speaker’s Bureau: Advanced Accelerator Applications;Financial Interests, Personal, Research Grant, Research funding: Merck Serono. T. Quintanar Verduguez: Financial Interests, Personal, Invited Speaker: Novartis;Financial Interests, Personal, Advisory Role: Novartis;Financial Interests, Personal, Invited Speaker: Abbott;Financial Interests, Personal, Invited Speaker: Nestle;Financial Interests, Personal, Advisory Role: Lilly;Financial Interests, Personal, Invited Speaker: Roche;Financial Interests, Personal, Other, Consultancy: Astra Zeneca. M. Sánchez Cánovas: Financial Interests, Personal, Invited Speaker: Leo Pharma;Financial Interests, Personal, Invited Speaker: Angelini Pharma;Financial Interests, Personal, Invited Speaker: KyowaKirin;Financial Interests, Institutional, Other: Leo Pharma;Other, Personal, Other, Attending Symposia: Sanofi;Other, Personal, Other, Attending Symposia: MSD;Other, Personal, Other, Attending Symposia: Esteve;Other, Personal, Other, Attending Symposia: Amgen;Other, Personal, Other, Attending Symposia: Servier;Other, Personal, Other, Attending Symposia: Angelini;Other, Personal, Other, Attending Symposia: Leo Pharma;Other, Personal, Other, Educational Programs: Angelini;Other, Personal, Other, Educational Programs: Sanofi;Other, Personal, Other, Educational Programs: Rovi;Other, Personal, Other, Educational Programs: Leo Pharma;Other, Personal, Other, Educational Programs: Servier;Other, Personal, Other, Educational Programs: Merck;Other, Personal, Other, Remunerations for authorship: KyowaKirin;Other, Personal, Other, Remunerations for authorship: Mylan. N. Tarazona: Financial Interests, Personal, Invited Speaker: Amgen;Financial Interests, Personal, Invited Speaker: Servier;Financial Interests, Personal, Invited Speaker: Pfizer;Financial Interests, Personal, Invited Speaker: Merck;Financial Interests, Institutional, Principal Investigator, Principal Investigator: Mutua Madrileña;Financial Interests, Institutional, Principal Investigator: SEOM;Financial Interests, Institutional, Principal Investigator: TTD Group;Non-Financial Interests, Personal, Leadership Role, Member of CIBERONC Liquid Biopsy Working Module since 2018: CIBERONC;Non-Financial Interests, Personal, Leadership Role, Member of ESMO Translational Research and Precision Medicine Working Group for the period 2019-2020.: ESMO;Non-Financial Interests, Personal, Leadership Role, Member of ESMO-MCBS Extended Working Group since 2019: ESMO;Non-Financial Interests, Personal, Leadership Role, Member of ESMO faculty member for the Gastro-Intestinal Tumours faculty group for the period 2019-2023.: ESMO Faculty;Non-Financial Interests, Personal, Leadership Role, Member of Executive Committee SEOM +MIR 2020-2022.: SEOM +MIR. A. Fernandez Montes: Financial Interests, Personal, Advisory Role: Bristol Myers Squibb;Financial Interests, Personal, Advisory Role: MSD;Financial Interests, Personal, Invited Speaker: MSD;Financial Interests, Personal, Invited Speaker: Servier;Financial Interests, Personal, Advisory Role: Lilly;Financial Interests, Personal, Invited Speaker: Lilly;Financial Interests, Personal, Advisory Role: Astra Zeneca;Financial Interests, Personal, Invited Speaker: Pierre Fabre;Financial Interests, Personal, Invited Speaker: Merck. E. Felip: Financial Interest , Personal, Advisory Board: Amgen;Financial Interests, Personal, Advisory Board: AstraZeneca;Financial Interests, Personal, Advisory Board: Bayer;Financial Interests, Personal, Advisory Board: Beigene;Financial Interests, Personal, Advisory Board: Boehringer-Ingelheim;Financial Interests, Personal, Advisory Board: Bristol Myers Squibb;Financial Interests, Personal, Advisory Board: Eli Lilly;Financial Interests, Personal, Advisory Board: F Hoffman-La Roche;Financial Interests, Personal, Advisory Board: Glaxo Smith Kline;Financial Interests, Personal, Advisory Board: Janssen;Financial Interests, Personal, Advisory Board: Medical Trends;Financial Interests, Personal, Advisory Board: Merck Sharp & Dohme;Financial Interests, Personal, Advisory Board: Merck Serono;Financial Interests, Personal, Advisory Board: Peptomyc;Financial Interests, Personal, Advisory Board: Pfizer;Financial Interests, Personal, Advisory Board: Puma;Financial Interests, Personal, Advisory Board: Regeneron;Financial Interests, Personal, Advisory Board: Sanofi;Financial Interests, Personal, Advisory Board: Syneos Health;Financial Interests, Personal, Advisory Board: Takeda;Financial Interests, Personal, Speaker’s Bureau: Amgen;Financial Interests, Personal, Speaker’s Bureau: AstraZeneca;Financial Interests, Personal, Speaker’s Bureau: Bristol Myers Squibb;Financial Interests, Personal, Speaker’s Bureau: Eli Lilly;Financial Interests, Personal, Speaker’s Bureau: F Hoffman-La Roche;Financial Interests, Personal, Speaker’s Bureau: Janssen;Financial Interests, Personal, Speaker’s Bureau: Medscape;Financial Interests, Personal, Speaker’s Bureau: Merck Sharp & Dohme;Financial Interests, Personal, Speaker’s Bureau: Merck Serono;Financial Interests, Personal, Speaker’s Bureau: Peervoice;Financial Interests, Personal, Speaker’s Bureau:Pfizer;Financial Interests, Personal, Speaker’s Bureau: Springer;Financial Interests, Personal, Speaker’s Bureau: Touch MEdical;Other, Personal, Other, Independent member of the board: GRIFOLS. A. Rodríguez-Lescure: Financial Interests, Personal, Advisory Role: Roche;Financial Interests, Personal, Advisory Role: Pfizer;Financial Interests, Personal, Advisory Role: Novartis;Financial Interests, Personal, Advisory Role: Lilly;Financial Interests, Personal, Advisory Role: MSD;Financial Interests, Personal, Advisory Role: Astra Zeneca;Financial Interests, Institutional, Funding: Roche;Financial Interests, Institutional, Funding: Novartis;Financial Interests, Institutional, Funding: Pfizer;Financial Interests, Institutional, Funding: Lilly;Financial Interests, Institutional, Funding: Astra Zeneca;Financial Interests, Institutional, Funding: Amgen;Financial Interests, Institutional, Funding: MSD;Financial Interests, Institutional, Funding: Bristol-Myers Squibb;Financial Interests, Personal, Invited Speaker: Roche;Financial Interests, Personal, Invited Speaker: Pfizer;Financial Interests, Personal, Invited Speaker: Novartis;Financial Interests, Personal, Invited Speaker: Lilly;Financial Interests, Personal, Invited Speaker: AstraZeneca;Financial Interests, Personal, Invited Speaker: MSD;Financial Interests, Personal, Invited Speaker: Merck;Other, Personal, Other, Travel, accommodations: Roche;Other, Personal, Other, Travel, accomodations: Pfizer. M.E. Elez Fernandez: Financial Interests, Personal, Advisory Board: Amgen;Financial Interests, Personal, Advisory Board: Array Biopharma;Financial Interests, Personal, Advisory Board: Bayer;Financial Interests, Personal, Advisory Board: Bristol Myers Squibb;Financial Interests, Personal, Advisory Board: Hoffman La- Roche;Financial Interests, Personal, Advisory Board: Merck serono;Financial Interests, Personal, Advisory Board: Sanofi;Financial Interests, Personal, Advisory Board: Servier;Financial Interests, Institutional, Research Grant: Abbvie;Financial Interests, Institutional, Research Grant: Amgen;Financial Interests, Institutional, Research Grant: Array Pharmaceuticals;Financial Interests, Institution l, Research Grant: AstraZeneca;Financial Interests, Institutional, Research Grant: Boehringer Ingelheim;Financial Interests, Institutional, Research Grant: Bristol-Myers Squibb;Financial Interests, Institutional, Research Grant: GlaxoSmithKline;Financial Interests, Institutional, Research Grant: Hoffman La-Roche;Financial Interests, Institutional, Research Grant: Medimmune;Financial Interests, Institutional, Research Grant: Merck Serono;Financial Interests, Institutional, Research Grant: MSD;Financial Interests, Institutional, Research Grant: Novartis;Financial Interests, Institutional, Research Grant: Pierre-Fabre;Financial Interests, Institutional, Research Grant: Sanofi Aventis. All other authors have declared no conflicts of interest.

SELECTION OF CITATIONS
SEARCH DETAIL